Last $64.29 USD
Change Today -2.07 / -3.12%
Volume 477.1K
RCPT On Other Exchanges
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

receptos inc (RCPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/22/14 - $68.20
52 Week Low
11/8/13 - $20.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECEPTOS INC (RCPT)

receptos inc (RCPT) Related Businessweek News

No Related Businessweek News Found

receptos inc (RCPT) Details

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

47 Employees
Last Reported Date: 08/12/14
Founded in 2008

receptos inc (RCPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $451.6K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $231.1K
Chief Financial Officer
Total Annual Compensation: $254.8K
Chief Medical officer
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.

receptos inc (RCPT) Key Developments

Receptos, Inc. Announces First Patient Treatment in Phase 2 Trial of RPC4046

Receptos, Inc. announced that the first patient has been treated in a Phase 2 trial of RPC4046, Receptos' development candidate for eosinophilic esophagitis (EoE). RPC4046 is a humanized monoclonal antibody directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications. The company has a development license and option agreement with AbbVie, Inc. to conduct a proof-of-concept clinical study with RPC4046 in EoE. Under the terms of the agreement, AbbVie holds an exclusive option to enter into a global co-development collaboration for RPC4046 with Receptos following results from the Phase 2 study and regulatory discussions with the FDA. Should AbbVie decline to exercise its co-development option, Receptos would obtain a worldwide exclusive commercial license to all indications for RPC4046. RPC4046 is a monoclonal antibody currently being studied for the treatment of eosinophilic esophagitis (EoE). EoE is a chronic immune-mediated disease that has been increasingly recognized by the medical community with a dramatic rise in its incidence and diagnosis. EoE may be triggered by a variety of stimuli including certain foods and environmental allergens. People with EoE commonly have other allergic conditions and may experience symptoms for months or years prior to diagnosis. EoE is typically associated with symptoms related to esophageal dysfunction, including food impaction and difficulty swallowing, which can have a profound impact on quality of life. While eliminating certain foods from diets may help some patients, there are no FDA-approved therapies. RPC4046 is directed against the interleukin-13 (IL-13) target, which has been validated in other allergy-related disorders including asthma. Receptos began enrollment of a randomized Phase 2 trial in the second half of 2014.

Receptos, Inc. - Special Call

To discuss the results of positive phase 2 trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos, Inc. Announces Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Receptos, Inc. announced consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaborative revenue of $1,100,000 against $1,238,000 a year ago. Loss from operations was $23,071,000 against $9,792,000 a year ago. Net loss attributable to common stockholders was $23,154,000 or $1.04 per basic and diluted share against $9,918,000 or $0.98 per basic and diluted share a year ago. The decrease in collaborative revenues during 2014 in comparison to the prior year reflects the termination of R&D funding from Ono in connection with the December 2013 amendment of agreement with them. For the six months, the company reported collaborative revenue of $2,450,000 against $2,726,000 a year ago. Loss from operations was $44,487,000 against $17,386,000 a year ago. Net loss attributable to common stockholders was $44,654,000 or $2.06 per basic and diluted share against $19,567,000 or $3.27 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPT:US $64.29 USD -2.07

RCPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPT.
View Industry Companies

Industry Analysis


Industry Average

Valuation RCPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 337.2x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 334.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECEPTOS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at